Autres langues BeiGene, Ltd. Deutsche Boerse AG

Actions

49B

KYG1146Y1017

Marché Fermé - Deutsche Boerse AG Autres places de cotation 08:20:01 26/06/2024			Varia. 5j.	Varia. 1 janv.
10,7 ^EUR	0,00 %		-2,73 %	-13,71 %

26/06	Un initié de Beigene a vendu des actions d'une valeur de 445 070 $, selon un récent dépôt auprès de la SEC	MT
20/06	Un initié de Beigene a vendu des actions d'une valeur de 368 162 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing	26/06
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing	20/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	17/06
BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index	17/06
EHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLL	15/06
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma	14/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region	14/06
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501	12/06
Beigene Issues Shares Under Incentive Schemes	12/06
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	10/06
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	04/06
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	28/05
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	24/05
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	24/05
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	24/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BeiGene, Ltd. Deutsche Boerse AG

Actions

49B

KYG1146Y1017

Autres langues

Filtres